CURE23h
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that it has dosed the first patient in the ...
Atai Life Sciences announces first patient dosed in Elumina Phase 2 trial
Life Sciences (ATAI) announced that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral ...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability ...
CURE12d
First Patient Dosed With HLD-0915 for mCRPC in First-In-Human Trial
The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant ...
Medindia1d
Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers
ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement SPRING HOUSE, Pa. /PRNewswire/ -- Third Arc Bio Inc., a clinical stage ...
Morningstar29d
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP ...